Yang Yong, Qiao Yuyu, Liu Ge, Chen Weihao, Zhang Ting, Liu Jing, Fan Weiping, Tong Mingwei
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China.
Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, and, Shanxi Key Laboratory of Cellular Physiology , Taiyuan, 030001, China.
Probiotics Antimicrob Proteins. 2024 Nov 7. doi: 10.1007/s12602-024-10393-2.
Inflammatory bowel disease (IBD) is a chronic immune-inflammatory disease. Gut microbes, intestinal immunity, and gut barrier function play a critical role in IBD. Growing evidence suggests that synbiotic may offer therapeutic benefits for individuals with colitis, suggesting an alternative therapy against colitis. With this in mind, we creatively prepared a new synbiotic combination consisting of a probiotic strain (Limosilactobacillus reuteri) along with one prebiotic chitooligosaccharides (COS). The protective effects of the synbiotic on DSS-induced colitis and the underlying mechanisms were investigated. We demonstrated that the synbiotic ameliorated colitis in mice, as evidenced by a significant remission in body weight loss and colon shortening, and a decreased disease activity index (DAI). Notably, synbiotic reduced the intestinal inflammation and injury by synergistically decreasing inflammatory factors, inhibiting TLR4/Myd88/NF-κB/NLRP3 signaling, preventing macrophage infiltration, and enhancing the integrity of the intestinal barrier. Moreover, synbiotic selectively promoted the growth of beneficial bacteria (e.g., Akkermansia, Lactobacillus) but decreased the pathogenic bacteria (e.g., Helicobacter). BugBase's analysis supported its ameliorated role in reducing pathogenic bacteria. Collectively, our findings revealed the novel synbiotic had a potential to treat colitis, which was associated with its anti-inflammatory and microbiota-balancing properties. This study will contribute to the development of functional synbiotic products for IBD therapy and will provide valuable insights into their mechanisms.
炎症性肠病（IBD）是一种慢性免疫炎症性疾病。肠道微生物、肠道免疫和肠道屏障功能在IBD中起关键作用。越来越多的证据表明，合生元可能对结肠炎患者具有治疗益处，这为治疗结肠炎提供了一种替代疗法。考虑到这一点，我们创造性地制备了一种新的合生元组合，由一种益生菌菌株（罗伊氏乳杆菌）和一种益生元壳寡糖（COS）组成。研究了该合生元对葡聚糖硫酸钠（DSS）诱导的结肠炎的保护作用及其潜在机制。我们证明，该合生元改善了小鼠的结肠炎，体重减轻和结肠缩短明显缓解以及疾病活动指数（DAI）降低证明了这一点。值得注意的是，合生元通过协同降低炎症因子、抑制TLR4/Myd88/NF-κB/NLRP3信号传导、防止巨噬细胞浸润以及增强肠道屏障的完整性来减轻肠道炎症和损伤。此外，合生元选择性地促进有益细菌（如阿克曼氏菌、乳杆菌）的生长，但减少病原菌（如幽门螺杆菌）。BugBase分析支持其在减少病原菌方面的改善作用。总的来说，我们的研究结果表明，这种新型合生元具有治疗结肠炎的潜力，这与其抗炎和微生物群平衡特性有关。这项研究将有助于开发用于IBD治疗的功能性合生元产品，并将为其作用机制提供有价值的见解。
